According to new analyses, nipocalimab-aahu (Imaavy) may help some people with antibody-positive generalized myasthenia gravis (gMG) maintain symptom improvements when added to standard care. Nipocalimab is approved by the U.S. Food and Drug Administration (FDA) for adults and children age 12 and older with anti-AChR-positive or anti-MuSK generalized MG.

In post hoc analyses of the phase 3 Vivacity-MG3 trial, participants who’d been diagnosed with gMG within five years before joining the study had greater improvements in daily functioning after 24 weeks with nipocalimab than with a placebo (inactive treatment).

Benefits were also seen in participants who entered the trial with less severe symptoms and in those who developed common infections during the study. In some people with MG, infections can trigger worsening MG symptoms.

🗳️ Have you had antibody testing for myasthenia gravis (MG)?

Yes, I tested positive for AChR antibodies.

Yes, I tested positive for MuSK antibodies.

Yes, I tested negative for MG antibodies (seronegative MG).

No, I haven’t had antibody testing for MG.

Thanks! You've successfully submitted your vote.

Sign up to view the results!

Continue with Facebook

Continue with Google

Continue with Email

By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data and Privacy policies.

Already a member? Log In

These findings matter because gMG symptoms can be unpredictable, and infections may trigger symptom worsening. The analyses suggest that some people taking nipocalimab may be able to maintain symptom control during these periods.

What Is Imaavy?

Nipocalimab is a neonatal Fc receptor (FcRn) blocker. FcRn blockers lower levels of immunoglobulin G (IgG) antibodies, including the harmful autoantibodies involved in generalized MG. In MG, these autoantibodies disrupt communication between nerves and muscles. This can cause muscle weakness, fatigue, trouble swallowing, and other symptoms.

What the New Analyses Found

The new findings come from post hoc analyses, meaning researchers looked more closely at subgroups after the trial had already been designed and completed.

One analysis focused on people who had been diagnosed with generalized MG within the previous five years. After 24 weeks, people treated with nipocalimab had a 4.9-point drop in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores compared with a 2.7-point drop in the placebo group.

MG-ADL scores range from 0 to 24 and track how symptoms affect everyday activities such as talking, chewing, swallowing, brushing teeth, and getting up from a chair.

The researchers also found that:

• In the same early-diagnosis subgroup, Quantitative Myasthenia Gravis (QMG) scores improved by 5.1 points with nipocalimab and 2.3 points with placebo. QMG measures muscle weakness and overall severity of MG on a scale of 0 to 39.
• People in that subgroup were more likely to have a clinically meaningful improvement in MG-ADL that lasted at least 20 weeks.
• Among people who started the trial with a lower symptom burden, MG-ADL scores improved by 4.5 points with nipocalimab and 2.3 points with a placebo.
• In that lower-symptom subgroup, QMG scores improved by 5.2 points with nipocalimab and 1.9 points with placebo.
• Among participants who developed common infections, MG-ADL scores stayed stable with nipocalimab but worsened by about 1 point with a placebo.

Join the Conversation

On MGteam, people share their experiences with myasthenia gravis, get advice, and find support from others who understand.

Have you talked with your doctor about antibody testing or newer targeted treatments for generalized MG? Let others know in the comments below.